What is Greenwich LifeSciences Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Greenwich LifeSciences's Probability of Financial Distress (%) is 0.10%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Greenwich LifeSciences's Probability of Financial Distress (%)
For the Biotechnology subindustry, Greenwich LifeSciences's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Probability of Financial Distress (%) falls into.
Greenwich LifeSciences Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -6.90 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.10% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
| Snehal Patel |
director, officer: CHIEF EXECUTIVE OFFICER |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Jaye Thompson |
officer: VPC AND REGULATORY AFFAIRS |
2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380 |
| Frank Joseph Daugherty |
director, officer: CHIEF MEDICAL OFFICER |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Kenneth Hallock |
director |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| David Mcwilliams |
director |
2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816 |
| Eric Rothe |
director |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Kinnary Patel |
10 percent owner |
3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477 |
| Panjaj Amrit Patel |
10 percent owner |
50726 LAKESIDE DRIVE, GRANGER IN 46530 |
Greenwich LifeSciences (Greenwich LifeSciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your